Bodycote Plc shares declined by over 2% on Thursday after RBC Capital Markets lowered its recommendation on the British heat-treatment company, arguing that recent gains had pushed the stock back to a decade-average valuation and left limited near-term upside.
RBC analyst Mark Fielding reduced his rating to "sector perform" from "outperform" but left the price target at 775p, implying roughly 1% upside from Wednesday's close of 764p. The firm highlighted that the stock's forward price-to-earnings multiple stands at 15.4x on 2026 estimates - in line with the company's 10-year average.
Fielding pointed to a mixed demand backdrop as a constraint on organic expansion, stating, "End markets are still mixed somewhat limiting organic growth." In his model he trimmed 2026 earnings-per-share to 49.74p, a 2% reduction from his prior view, and lowered revenue expectations to
Correction: The revenue figure above contains a formatting error and should be read as
RBC's update also lays out a multi-year margin improvement plan that Bodycote itself has reaffirmed. The company is targeting a 20% EBITA margin for 2028, up from 15.7% recorded in 2025. Part of the planned improvement stems from site consolidation: the company expects to realise
RBC projects EBITA to climb from
In assessing free cash flow, RBC noted a yield of 4%, which it views as less compelling compared with the 8%-9% free cash flow yield that supported its October 2024 upgrade. The firm cites capital spending as a factor weighing on near-term cash conversion.
RBC also published scenario analysis. Its upside case values the shares at 975p and assumes a faster recovery in end markets, with EPS of around 65p and a 15x earnings multiple. The downside case sets a value of 390p, assuming earnings decline to roughly 28p - levels seen in 2020 - at a 14x multiple.
Bodycote's end-market exposure mix is central to the firm's outlook. RBC expects revenue tied to higher-growth sectors to increase from 35% of sales in fiscal 2023 to 45% following planned site disposals, with a longer-term goal of exceeding 50% by 2028. The 2026 growth picture is uneven: aerospace and defence, accounting for 34% of sales, is forecast to post high-single to low-double-digit volume growth, while automotive and industrials, which make up 43% of group sales, remain under pressure. The industrial gas turbine subsegment expanded by 6% in 2025, trailing Siemens Energy's 14% growth in the same area.
RBC flagged that the operating leverage inherent in its forecasts is about 30%, which it characterised as solid but not standout versus peers.
Key points
- RBC cut Bodycote to "sector perform" from "outperform" and kept the 775p price target unchanged.
- Forward P/E is 15.4x on 2026 estimates, matching the 10-year average; 2026 EPS trimmed to 49.74p and revenue forecast slightly lowered.
- Margin plan aims for 20% EBITA by 2028, supported by site consolidation savings and broader operational improvements; EBITA forecast to rise to by 2028.
Risks and uncertainties
- End-market weakness: Automotive and industrials represent 43% of sales and remain challenged, which could limit growth in those sectors.
- Cash conversion pressure: Free cash flow yield is 4%, below the 8%-9% level that previously supported an upgrade, with capital expenditure weighing on near-term cash generation.
- Execution risk on margin targets: Realising
Investors and market participants assessing Bodycote's near-term prospects will weigh the group's path to higher-margin, higher-growth end markets and the pace at which cost and site rationalisation translate into measurable profit and cash-flow gains.